Low-Dose Radiotherapy for Multiple Myeloma with Bone Pain
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores the effectiveness of low-dose radiotherapy, a form of palliative radiation therapy, in relieving bone pain for people with multiple myeloma, a type of blood cancer that often spreads to the bones. The goal is to determine if this lower dose of radiation can effectively reduce pain while causing fewer side effects than traditional treatments. The trial suits those with painful bone lesions from multiple myeloma that align with their imaging results and have not received radiation at the pain site before. Participants may receive additional treatment if initial pain relief is not achieved. As an unphased trial, this study provides an opportunity to explore innovative pain relief options that could improve quality of life.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop your current medications, but it allows changes to systemic therapy or use of bisphosphonates (medications that prevent bone loss) for 4 weeks before and after the radiation therapy.
What prior data suggests that low-dose radiotherapy is safe for treating bone pain in multiple myeloma patients?
Research has shown that low-dose radiotherapy is generally well-tolerated by patients with multiple myeloma who experience bone pain. In one study, 92% of painful areas improved significantly after treatment, indicating that this therapy can effectively manage pain. Another study found that low-dose radiotherapy reduced pain without causing serious side effects.
While these studies are promising, not all patients will experience pain relief. Up to 40% might not feel better after the first treatment, and some may have pain return within a year. However, the findings suggest that the treatment is relatively safe, with most patients experiencing only minor side effects.12345Why are researchers excited about this trial?
Researchers are excited about low-dose radiotherapy for multiple myeloma with bone pain because it offers a potentially faster and more targeted relief option compared to the standard treatments like chemotherapy and higher-dose radiation. Most traditional treatments can take weeks to show significant pain relief, but low-dose radiotherapy might provide quicker results in just a few days. Additionally, this approach could minimize side effects due to the lower radiation levels, making it a potentially safer option for patients who are sensitive to more aggressive treatments.
What evidence suggests that low-dose radiotherapy is effective for bone pain in multiple myeloma?
Research has shown that low-dose radiotherapy, which participants in this trial will receive, can effectively ease bone pain in people with multiple myeloma. In one study, 92% of painful areas experienced significant pain relief after treatment. Another study found that 85% of patients had pain relief lasting at least a year. These findings suggest that low-dose radiotherapy not only reduces pain but also maintains relief for an extended period, making it a promising option for managing bone pain linked to multiple myeloma.12367
Who Is on the Research Team?
Adam Garsa, MD
Principal Investigator
University of Southern California
Are You a Good Fit for This Trial?
This trial is for patients with multiple myeloma and painful bone metastases. Participants must have a pain score of at least 2, confirmed diagnosis, and be able to consent. They can have had any number of prior treatments but should not be pregnant or have received radiation on the index lesion.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Radiation
Participants receive low-dose radiation therapy at consecutive business days 1 and 2
Follow-up
Participants are monitored for pain relief and quality of life after radiation therapy
What Are the Treatments Tested in This Trial?
Interventions
- Low-Dose Radiotherapy
Low-Dose Radiotherapy is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
- Painful bone metastases from multiple myeloma
- Symptomatic relief of bone pain
- Painful bone metastases from multiple myeloma
- Symptomatic relief of bone pain
- Spinal cord compression
- Painful bone metastases from multiple myeloma
- Symptomatic relief of bone pain
- Painful bone metastases from multiple myeloma
- Symptomatic relief of bone pain
- Painful bone metastases from multiple myeloma
- Symptomatic relief of bone pain
- Painful bone metastases from multiple myeloma
- Symptomatic relief of bone pain
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Southern California
Lead Sponsor
National Cancer Institute (NCI)
Collaborator